Portland Investment Counsel Inc. Takes $2 Million Position in Lantheus Holdings, Inc. $LNTH

Portland Investment Counsel Inc. purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 18,000 shares of the medical equipment provider’s stock, valued at approximately $1,997,000. Lantheus makes up approximately 0.6% of Portland Investment Counsel Inc.’s portfolio, making the stock its 25th largest holding.

A number of other hedge funds have also recently made changes to their positions in the stock. Western Wealth Management LLC bought a new stake in Lantheus during the first quarter valued at about $25,000. Smartleaf Asset Management LLC raised its holdings in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Parallel Advisors LLC raised its holdings in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares in the last quarter. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus during the second quarter valued at about $36,000. Finally, Bessemer Group Inc. lifted its position in shares of Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Lantheus stock opened at $99.97 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The stock has a market cap of $6.53 billion, a PE ratio of 24.15 and a beta of -0.03. The stock has a 50-day moving average of $104.08 and a two-hundred day moving average of $90.52. Lantheus Holdings, Inc. has a one year low of $49.67 and a one year high of $111.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. During the same quarter in the previous year, the firm earned $1.57 earnings per share. The company’s revenue was up 2.7% on a year-over-year basis. On average, research analysts anticipate that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of recent analyst reports. CJS Securities downgraded shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Mizuho reduced their price objective on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday, July 29th. The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Citizens Jmp restated a “market outperform” rating and issued a $115.00 target price on shares of Lantheus in a research note on Monday, June 29th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $108.11.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.